RE:RE:RE:no volumeThis could be the scenario and my thoughts on why the share price should not influence why we are here for the prize (to me it's still the BG pill);
Gilles doesn't want a " Mickey Mouse" PGX deal and had already rejected one. We are playing with the big boys here. Gille recognized the effort required to get a deal that suits the company. He hired a consulting firm to handle the negotiations.
We are a SME with no large scale commercial PGX products.A large multinational company will not sign a PGX agreement when Ceapro does not have a plant that would be able to meet their production demands.
The German plant could be used by Ceapro to go alone on the a successful BG pill. The BG study is due in mid-2021 and Noble's analyst had called for scale up of a PGX plant in mid-2021 as well. The "premature" announcement of the German plant could also demonstrate to interested parties that Ceapro will have production capacity if that decision was not based on having a partner fully committed.
As others have mentioned, there could be some NDA involved here. PGX is a breakthrough tech and being able to load various substrates with bio-actives could be a game changer in various industries. A multi-national would have a big advantage over it's rivals with these type of chemical complexes. Secrecy is likely a key principle at play until the ink is dry on a contract.
Of course I could be half right, but the story is still unfolding, it's just taking more page flipping to get to the next chapter: a PGX deal.